Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
Inventors
Cai, Xiong • Zhai, Haixiao • Lai, Chengjung • Qian, Changgeng
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The instant application relates to deazapurines, thienopyrimidines and furopyrimidines with zinc-binding moiety based derivatives and their use in the treatment of phosphoinositide 3-kinase related diseases and disorders such as cancer. The instant application further relates to the treatment of histone deacetylase related disorders and diseases related to both histone deacetylase and phosphoinositide 3-kinase.
Core Innovation
The disclosure provides compounds having a specified chemical formula in which a substituent R is selected from the group consisting of hydrogen, methyl, n-propyl, n-butyl, 2-hydroxyethyl, 2-methoxyethyl, and isobutyl. The description further relates to substituted PI3K/HDAC inhibitor scaffold variations, morpholinothieno[3,2-d]pyrimidine-based derivatives, hydroxypyrimidine carboxamide derivatives, and a common fused heteroaromatic core with a thioether linkage and a morpholine-like ring.
Preferred embodiments are described by preferred subsets of substituents within the generic formulas, including preferred G1, preferred u and t, a preferred G5 fragment pattern, preferred relationships for m with associated R3 options, and a most preferred C substituent fragment with R33 limited to hydrogen or lower alkyl. The chemical structure depictions show variation in peripheral functional groups, terminal heteroaryl substituents, and pendant groups while retaining the shared scaffold.
The compounds are characterized with LCMS [M+1], 1H NMR, and mp, and the document includes biological evaluation of PI3Kα/β/γ/δ, HDAC inhibition, and mTOR kinase inhibition with IC50 values and tabulated activity grading. Cell proliferation antiproliferative readouts are also included using ATP-based assays, and certain preferred embodiments are stated to have significant inhibitory activity toward PI3 kinase and HDAC, and possibly mTOR.
Claims Coverage
The consolidated claim coverage centers on one compound formula family with one inventive selection element: substituent R. Across the provided material, the independent claim allows seven R options, and dependent claims narrow R to hydrogen or methyl and then to single-option embodiments. In total, the claim set presents one core inventive feature expressed through a defined R selection.
Compound formula with defined R substituent set
A compound of the formula wherein R is selected from the group consisting of hydrogen, methyl, n-propyl, n-butyl, 2-hydroxyethyl, 2-methoxyethyl, and isobutyl.
R narrowed to hydrogen or methyl
The compound wherein R is selected from the group consisting of hydrogen and methyl.
R set to hydrogen
The compound wherein R is hydrogen.
R set to methyl
The compound wherein R is methyl.
Across the independent claim and dependent refinements, the claims focus on a specified formula with substituent R limited to a defined set, then narrowed to hydrogen or methyl and finally to single-option embodiments.
Stated Advantages
Zinc-binding is described as enabling multi-target activity, including PI3K inhibition and inhibition of HDAC and/or MMP by zinc binding.
The document states potential additional mTOR inhibition as part of the multi-target profile.
The document argues for synergy versus separate PI3K and HDAC inhibitors.
Significant inhibitory activity toward PI3 kinase and HDAC is stated for certain preferred embodiments, and possibly mTOR.
Documented Applications
Methods of treating and preventing cancer and other conditions involving aberrant cell proliferation or survival, including hematological cancers.
Modulation of lymphocyte counts, including effects relevant to lymphopenia and circulating lymphocyte count.
Combination therapy with other antineoplastic agents and additional therapeutic modalities including kinase modulators, HDAC inhibitors, DNMT-related targets, chemotherapeutics, radiation therapy, and immunotherapeutic agents.
Treating PI3K-related diseases, including cancer.
Biological evaluation for PI3Kα/β/γ/δ inhibition, HDAC inhibition, and mTOR kinase inhibition, with IC50 values and cell proliferation antiproliferative readouts using ATP-based assays.
Interested in licensing this patent?